A HeV G glycoprotein subunit vaccine, Equivac® HeV, which breaks the chain of zoonotic transmission from bats to horses to humans, is licensed for horse vaccination in Australia and is also a promising human vaccine antigen candidate that is protective against HeV or NiV challenge in ferret and non-human primate infection models [83–86]. Here, THBS1 is linked to infection.